Biogen’s financial report for 2025 showed a decline in quarterly revenue and adjusted profitability, yet still beat analyst estimates. The stock surged nearly 9% on the news. Despite revenue dropping 7% to $2.28 billion, Biogen exceeded expectations with $1.99 per share in non-GAAP net income. Product revenue fell 9%, mainly due to a decline in multiple sclerosis treatments. Biogen’s guidance for 2026 predicts a mid-single digit revenue decline, but adjusted net income is expected to be higher than analyst estimates. The company’s focus on new medicines and pipeline growth is driving investor confidence.

Read more at NASDAQ.: Why Biogen Stock Surged Almost 9% Higher on Friday